Pharmalink AB has received orphan drug designation from the FDA for Busulipo, a conditioning agent for use in cancer patients prior to hematopoietic stem cell transplantation (HSCT; also known as bone marrow transplantation). The Company is currently preparing for registration trials with an optimized formulation of Busulipo as part of its plans to advance the product towards the market. Busulipo was developed by Pharmalink as a liposome/lipid complex formulation that improves the safety and st...